Weight Loss Medications Compared: Semaglutide, Tirzepatide, Phentermine & More

The weight loss medication landscape has transformed dramatically in the past five years. What was once a field defined by modestly effective stimulants and fat blockers is now home to medications that can produce bariatric-surgery-level results without the operating room.

But with more options comes more confusion. Patients ask: Is semaglutide better than tirzepatide? Is phentermine still worth considering? What about the over-the-counter options? This guide cuts through the noise with a complete, evidence-based comparison of every major weight loss medication available in 2026.

All Major Weight Loss Medications at a Glance

Weight loss percentages represent average outcomes in clinical trials on active medication. Individual results vary based on adherence, lifestyle factors, and individual response. GLP-1 costs reflect Truventa Medical compounded pricing.

GLP-1 Medications: The Clear Winners for Efficacy

Semaglutide and tirzepatide have fundamentally changed what's possible with pharmacological weight management. They work by mimicking gut hormones that regulate appetite, slow gastric emptying, and signal satiety — addressing the biological root causes of obesity rather than just suppressing appetite through stimulant effects.

Why GLP-1s Are Different

Unlike older weight loss medications that primarily work on willpower (suppressing appetite through stimulants) or blocking fat absorption, GLP-1 receptor agonists work on the hypothalamus — the brain's hunger-control center. They reduce what many patients call "food noise" — the constant mental preoccupation with eating and food.

Clinical outcomes are equally dramatic in the real world. The SELECT cardiovascular outcomes trial showed semaglutide also reduced major cardiovascular events by 20% in high-risk patients — the first weight loss medication to demonstrate such CV benefits.

For a detailed head-to-head comparison, read our Tirzepatide vs Semaglutide article.

Phentermine: Old-School, Cheap, Limited Long-Term Data

Phentermine has been FDA-approved since 1959, making it one of the oldest weight loss medications. It works by releasing norepinephrine, which suppresses appetite through stimulant effects — similar in mechanism to amphetamines, though significantly milder.

Pros: Extremely cheap ($15-30/month generic), works quickly, widely available, effective short-term

Cons: Only FDA-approved for short-term use (typically 12 weeks). After stopping, weight regain is common. Cannot be used in patients with heart disease, hypertension, hyperthyroidism, or glaucoma. Potential for dependence as a Schedule IV controlled substance. No long-term cardiovascular outcomes data.

Verdict: Phentermine can be useful as a short-term bridge or for patients who are not GLP-1 candidates. For sustained, significant weight loss, GLP-1 medications produce substantially better long-term results.

Orlistat: OTC Option, Minimal Efficacy, Unpleasant Side Effects

Orlistat works by blocking the absorption of approximately 30% of dietary fat in the gut. Unlike other weight loss medications, it doesn't affect the brain or appetite — it simply prevents fat from being absorbed.

Pros: Available over-the-counter, no systemic effects, no drug interactions with CNS

Cons: The GI side effects of orlistat are notoriously unpleasant — oily stools, fecal urgency, oily spotting, and flatulence with oily discharge are common, particularly if dietary fat intake is high. These "treatment effects" occur as a direct consequence of the mechanism of action and are dose-dependent on fat consumption. The 3-5% average weight loss is among the lowest of any approved medication.

Verdict: Orlistat is rarely a first choice for patients with significant weight to lose. It may have a role for patients who cannot tolerate any other options.

Combination Pills: A Decent Middle Ground

Qsymia® (phentermine + topiramate ER) produces more weight loss than phentermine alone by adding topiramate, which independently reduces appetite and caloric intake. With ~9% average weight loss, it outperforms the older single-agent options. However, topiramate is teratogenic — meaning it causes birth defects — making it inappropriate for women of reproductive age without reliable contraception. Cognitive side effects ("brain fog") are common.

Contrave® (naltrexone + bupropion) works on two distinct pathways: bupropion activates reward centers while naltrexone blocks the feedback loop that normally blunts this activation. The result is reduced cravings and appetite. With 5-8% weight loss, it's meaningful but significantly below GLP-1 performance. Notable contraindication: cannot be used in patients with seizure disorders or those taking opioids.

Verdict: Combination pills fill an important niche for patients who cannot use GLP-1s but need more than phentermine alone. For patients who are GLP-1 candidates, however, the superior efficacy of semaglutide and tirzepatide makes them the preferred option.

Who Is a Candidate for GLP-1 Medications?

GLP-1 receptor agonists are FDA-approved for adults with:

• BMI ≥ 30 (obesity) — no additional conditions required
• BMI ≥ 27 (overweight) plus at least one weight-related comorbidity: type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease

GLP-1 medications are not appropriate for patients with:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple endocrine neoplasia syndrome type 2 (MEN 2)
• History of pancreatitis
• Pregnancy or planned pregnancy
• Known hypersensitivity to semaglutide or tirzepatide

At Truventa Medical, our online health intake evaluates your eligibility based on these criteria and your full health history. Most adults seeking weight management are appropriate candidates for GLP-1 treatment.

The Future: What's Coming Next

The field is moving rapidly. What represents best-in-class today may be surpassed within 24 months. Truventa Medical will incorporate new evidence-based options as they receive approval and become available.

The Bottom Line

For most adults with obesity or overweight who are appropriate candidates, the evidence strongly favors GLP-1 medications as the first-line pharmacological treatment in 2026:

• Tirzepatide offers the highest efficacy at 20.9% average weight loss — the clear choice for patients who want maximum results
• Semaglutide offers excellent efficacy at 14.9%, a longer track record, and the lowest cost at $199/mo — ideal for most patients
• Phentermine and combination pills remain reasonable options for patients who are not GLP-1 candidates or need short-term options
• Orlistat is rarely a preferred option given limited efficacy and difficult side effect profile